The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

November 1, 2026 edition — delayed release. This recap covers October 26–30; its dated week-ahead items reflect preparation-time previews, not subsequently reported results. The FDA removed the cardiovascular disease, breast cancer and probable dementia risk statements from the boxed warnings on the Minivelle, Vivelle and Vivelle-Dot estradiol patches; Minivelle keeps its endometrial cancer box, and all three remain prescription products. Novartis took a $1.94 billion partial, noncash impairment on del-desiran after September's HARBOR miss, and Acumen ended sabirnetug after its Phase 2 Alzheimer's trial reduced plaque but missed on cognition and function. We also cover the FDA approval of Talzenna (talazoparib) plus Xtandi (enzalutamide), Lilly's retatrutide head-to-head against Ozempic (semaglutide), Genmab's petosemtamab survival result, Ilumya's psoriatic arthritis approval and Agios's new mitapivat decision date. Then the dated week ahead: Pfizer, Novo Nordisk, Recursion, SITC and AHA.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

The Pharma Closeout's ESMO 2026 Debrief brings you the readouts from the European Society for Medical Oncology congress in Madrid that matter, what they change, and what to watch next, with one thread running through them: how much checkpoint therapy is enough. MOIO, a French trial that spaced checkpoint-inhibitor doses to every 12 weeks in patients already responding, was stopped early on its monitoring committee's recommendation. Around bladder surgery, Merck's KEYNOTE-866 and Bristol Myers Squibb's ENERGIZE both missed event-free survival in cisplatin-eligible patients, while VOLGA won in patients ineligible for or declining cisplatin, and final PEARLS survival for adjuvant Keytruda in lung cancer missed significance. Then mismatch repair-deficient tumors, with a correction on GSK's AZUR-1 numbers; Akeso and Summit's ivonescimab beating AstraZeneca's Imfinzi on survival in biliary tract cancer at an interim analysis; Tagrisso plus Orpathys in two lines of lung cancer; Amgen's Imdelltra and a rival DLL3 drug in small-cell lung cancer; six-year NATALEE survival for Novartis's Kisqali; androgen-receptor drugs moving earlier in prostate cancer; and cancer vaccines, led by Merck and Moderna's intismeran. Plus what to watch: INTerpath-001's full results, slated for The New England Journal of Medicine on November 11, and the November 14 FDA goal date for ivonescimab in EGFR-mutated lung cancer.

0:00 Cold open and introduction

1:03 Story of the Congress: how much checkpoint is enough (MOIO, KEYNOTE-866, ENERGIZE, VOLGA, PEARLS)

5:45 Mismatch repair-deficient tumors: KEYNOTE-C93, TroFuse-005, the AZUR-1 correction and CheckMate 8HW

9:19 Biliary tract cancer: ivonescimab beats Imfinzi in HARMONi-GI1

10:43 Lung cancer: SAFFRON, SANOVO, sigvotatug vedotin and PERSEE

13:18 Small-cell lung cancer: DeLLphi-305, ASTRIDE and IDE849

14:37 Breast cancer: NATALEE at six years and postMONARCH

15:53 Prostate cancer: PROTEUS, DASL-HiCaP and J&J's RIPTAC

17:50 Cancer vaccines: intismeran, ELI-002 7P and DOVACC

19:08 What to watch: INTerpath-001 in NEJM and the ivonescimab FDA decision

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

October 30 edition — delayed release on November 1. References to today and Friday in the audio refer to October 30.

Acumen ends sabirnetug after a Phase 2 Alzheimer's trial lowered amyloid but missed on cognition and function, and Inovio's Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) won accelerated approval for adult recurrent respiratory papillomatosis, with benefit yet to be verified. Sun Pharma's Ilumya (tildrakizumab-asmn) is approved for active psoriatic arthritis, Agios' mitapivat sickle cell action date moved to February 1, 2027, and NRx says FDA approved its generic preservative-free ketamine. Dren Bio raised $350 million for dibotatug, and Setara $90 million for STAR-0871 in CMT2C. Regeneron's Eylea (aflibercept) and Sanofi's Dupixent (dupilumab) quarters and Nxera's operating-profit swing close it out.

October 29, 2026 edition, released October 30. The audio reflects the October 29 roundup; the INO-3107 watch refers to an October 30 FDA target date, not an announced decision.

Iovance's lifileucel produced responses in 17 of 69 previously treated non-squamous lung cancer patients who received at least 10 billion viable cells. A new cohort, POSITILITY, will select patients up front using a subgroup profile found in a retrospective analysis. Ono's ONO-1110 missed primary endpoints in three Phase 2 pain studies; Ono is planning further pain studies based on prespecified subgroup and post hoc signals, and plans no further studies in depression or social anxiety. The daily roundup covers BMS ending Prothena's PRX019 license, Rafael's remibetadex NDA in Niemann-Pick type C after a Phase 3 primary-endpoint miss, a BioMarin Fabry license, Alnylam's TRITON-CM expansion, Lilly and Merck third quarters, and a Labor Department PBM disclosure rule.

This is the October 28 edition of The Pharma Closeout, released October 29.

Genmab's investigational petosemtamab combination improves survival against pembrolizumab alone in a first-line head-and-neck cancer trial, while Lilly's retatrutide raises a dose-choice question after greater weight loss and more adverse-event discontinuations than Ozempic (semaglutide) 2 mg in type 2 diabetes. Geron stops imetelstat's myelofibrosis trial; AbbVie files etentamig for multiple myeloma using previously reported CERVINO results; and Replimune reports early launch activity for TUDRIQEV (vusolimogene oderparepvec-wtpg) in melanoma. FDA's draft individualized gene-editing framework, CMS's planned gene-therapy access expansion and HHS's proposed conditional peptide-compounding policy remain distinct developments. GSK's sales mix shifts toward specialty medicines, and FDA staff questions set up the October 30 advisory committee on Sydnexis's atropine for pediatric myopia.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Artiva ends AlloNK and cuts about 94% of staff after a risk-benefit review covering durability and two separately assessed deaths. Ferring agrees to acquire Gameto for up to $1.3825 billion subject to milestones, before Fertilo's pivotal fertility trial reports. Pfizer's ELREXFIO (elranatamab) meets a Phase 3 myeloma goal with higher rates of severe infections; AstraZeneca and Daiichi Sankyo gain EU approval for Enhertu (trastuzumab deruxtecan) in postoperative HER2-positive early breast cancer; Novartis discontinues remibrutinib in generalized myasthenia gravis for futility. Also: Teva closes its BioXcel asset deal for IGALMI (dexmedetomidine) and the pending at-home BXCL501 program; Vanda's NEREUS (tradipitant) reduces vomiting in a single-dose semaglutide challenge; and Kiniksa raises its ARCALYST (rilonacept) sales forecast.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

October 26, 2026 edition, released October 27. Recorded October 26: references to today mean October 26, and tomorrow means October 27.

BioNTech and DualityBio's breast cancer ADC beat chemo in Phase 3, yet the companies call the gain modest. Merck and Kelun's sac-TMT showed interim median overall survival of 19.0 vs 12.1 months in endometrial cancer after platinum and immunotherapy and is under FDA priority review. Also: Keytruda (pembrolizumab) alone in first-line dMMR endometrial cancer; FDA approval of Talzenna (talazoparib) plus Xtandi (enzalutamide) for adults with metastatic, androgen pathway modulation-naive or -sensitive prostate cancer with HRR mutations detected by an FDA-authorized test; BMS/SystImmune's iza-bren in EGFR-mutated lung cancer; GSK/Hansoh's ris-rez in osteosarcoma; and Corxel US/Amanat's proposed deal that would help fund oral GLP-1 CX11.

Sources:
- SEC (BioNTech Exhibit 99.1): DYNASTY-Breast02 topline Phase 3 results for trastuzumab pamirtecan — October 26, 2026 — https://www.sec.gov/Archives/edgar/data/0001776985/000177698526000074/a991261025_bntxdbxtpamxtop.htm
- FDA: Approval of fam-trastuzumab deruxtecan-nxki in HR-positive HER2-low or HER2-ultralow metastatic breast cancer — January 2025 — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2
- Merck: TroFuse-005 sacituzumab tirumotecan endometrial results and FDA priority review — October 26, 2026 — https://www.merck.com/news/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial/
- Merck: KEYNOTE-C93 Keytruda monotherapy in dMMR endometrial cancer — October 26, 2026 — https://www.merck.com/news/keytruda-pembrolizumab-as-monotherapy-reduced-the-risk-of-disease-progression-or-death-by-43-for-certain-patients-with-advanced-or-recurrent-endometrial-cancer-with-mismatch-repair-deficient/
- FDA: Approval of talazoparib with enzalutamide in metastatic androgen pathway modulation-naive or -sensitive prostate cancer — October 26, 2026 — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive
- Bristol Myers Squibb: PANKU-Lung01 Phase 3 results for izalontamab brengitecan — October 26, 2026 — https://news.bms.com/news/corporate-financial/2026/Izalontamab-Brengitecan-Iza-Bren-Doubles-Median-Progression-Free-Survival-in-Patients-with-Previously-Treated-EGFR-Mutated-Non-Small-Cell-Lung-Cancer-Compared-to-Chemotherapy-in-the-Phase-3-PANKU-Lung01-Study/default.aspx
- FDA: Approval of amivantamab-vmjw with carboplatin and pemetrexed after EGFR TKI — September 19, 2024 — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19
- GSK: ARTEMIS-011 ris-rez in relapsed osteosarcoma in China — October 26, 2026 — https://www.gsk.com/en-gb/media/press-releases/ris-rez-reduced-risk-of-disease-progression-or-death-by-67-versus-chemotherapy-in-patients-with-relapsed-osteosarcoma-in-china/
- SEC (Exhibit 99.1): Corxel and Amanat proposed business combination and financing — October 26, 2026 — https://www.sec.gov/Archives/edgar/data/2112457/000121390026112236/ea030895401ex99-1.htm
- FDA: Approval of talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer — June 20, 2023 — https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate

Sunday, October 25 edition, released Monday, October 26 with the SANOVO update. Amgen's Imdelltra plus AstraZeneca's Imfinzi extended median survival to 21.1 months from 12.7 in extensive-stage small-cell lung cancer maintenance, while Roche's divarasib beat pooled KRAS G12C comparators. AstraZeneca's Sone-Ve delivered a gastric-cancer survival win beside a missed progression endpoint; SANOVO then showed Tagrisso plus Orpathys improved progression-free survival in untreated, biomarker-selected patients in China. Gilead's $1.275 billion PepStar IL-23 deal and AbbVie's Skyrizi Crohn's approval lead gastroenterology, with hematology, immunology, diagnostics and biotech investment rules rounding out the full Week in Review.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Delayed release on October 24, 2026 of the Friday, October 23 edition. News and relative-date references are as of October 23.

Novartis's investigational remibrutinib cut MS relapse rates 35.2% and 31.2% versus teriflunomide; Biokin's Bristol Myers Squibb/SystImmune-partnered iza-bren improved breast cancer PFS. Jazz/BeOne's Ziihera (zanidatamab), licensed from Zymeworks, has mature gastroesophageal survival data, while Tango reports pancreatic cancer responses with vopimetostat and Revolution Medicines' daraxonrasib. Johnson & Johnson's Tecvayli (teclistamab) moves earlier in European myeloma treatment, as we examine BMS's zola-cel safety in MS and Alnylam's brezosiran target engagement in Huntington's. Plus Bolt's Prana acquisition and Treasury's proposed biotech investment rules.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

The Pharma Closeout's UEG Week 2026 Debrief covers the readouts from United European Gastroenterology Week in Barcelona that matter for drug, device and payer strategy. Takeda's VERDICT, the first randomized treat-to-target strategy trial in ulcerative colitis, and the new STRIDE-III guidance sharpen what IBD treatment should aim at, and what that means for how therapies win switches. Then the orals (Abivax's obefazimod ahead of its NDA, Gilead's emvistegrast dose curve, J&J's icotrokinra), the TL1A race with Teva and Sanofi's first 44-week duvakitug data, the incumbents' franchise defense from AbbVie and J&J, Tremfya at week 48 in Crohn's with fistulas, and a gastroparesis drug heading to Phase 3. Plus what to watch: AbbVie's October 30 results, AASLD from November 5 and the November 27 PBC decision.

0:00 Cold open and introduction

0:50 Story of the Congress: the target, not the molecule (Takeda's VERDICT, STRIDE-III, PROFILE)

5:06 The orals: obefazimod, emvistegrast, icotrokinra and OD-001

8:38 The TL1A race: Teva and Sanofi's duvakitug

10:01 Franchise defense: AbbVie, J&J, Spyre and the biosimilar squeeze

13:26 The IL-23 incumbents: Tremfya in fistulizing Crohn's, Skyrizi's subcutaneous induction

15:26 Beyond IBD: gastroparesis, EoE and the liver

17:27 What to watch: AbbVie's results, AASLD and the PBC decision

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

October 22, 2026 edition, released October 23. Reporting reflects the October 22 research cutoff.

Merck and Moderna's investigational intismeran autogene, added to Keytruda (pembrolizumab) after surgery for high-risk cutaneous melanoma, posted a 0.58 hazard ratio for recurrence or death versus placebo plus Keytruda; overall survival is immature. AbbVie's investigational lutikizumab beat placebo in a Phase 3 hidradenitis suppurativa trial, 31.4% versus 23.4% on HiSCR75. The daily roundup covers BioNTech's planned pairing of pumitamig with Gilead's Trodelvy (sacituzumab govitecan), Menarini subsidiary Stemline's GIM-621 license from Georgiamune, Cencora's American Oncology Network deal and Roche's removal of RG6540 from its Phase 1 pipeline. It also covers Krystal Biotech's Vyjuvek (beremagene geperpavec) storage update, Biohaven's statement, reported by Dow Jones, that FDA accepted its Vyglxia resubmission, and QIAGEN's agreed EQT-led acquisition.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

October 21, 2026 edition, released October 22. Relative dates in the audio refer to October 21.

Roivant's Priovant reports two positive Phase 3 trials of oral brepocitinib in non-infectious uveitis, run through a mandatory steroid taper. F2G and Shionogi add kidney, liver and hospital-stay detail from olorofim's OASIS trial, where survival was noninferior rather than better. Also in the daily roundup: Alcon completes its Neurotech acquisition, the European Commission approves perioperative Keytruda plus Padcev regardless of cisplatin eligibility, Summit and ECOG-ACRIN set up a trial of ivonescimab in biliary tract cancer, Roche discloses fenebrutinib lesion imaging ahead of its MSToronto presentation, TG releases data on a single-infusion Briumvi start, OpenAI acquires Orchestra Bio, and FDA's warning letter to Baxter becomes public.

Sources:
https://www.biospace.com/press-releases/roivant-and-priovant-announce-positive-results-in-clarity-1-and-clarity-2-phase-3-trials-for-brepocitinib-in-non-infectious-uveitis-niu
https://www.sec.gov/Archives/edgar/data/1635088/000114036126034854/ef20081283_ex99-1.htm
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5023a17b-e96a-67d4-e063-6394a90a14a7
https://www.shionogi.com/global/en/news/2026/10/e20261021_3.html
https://www.biospace.com/press-releases/alcon-acquires-neurotech-and-encelto-the-only-fda-approved-treatment-for-mactel-type-2
https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-perioperative-treatment-for-adults-with-resectable-muscle-invasive-bladder-cancer-mibc/
https://www.prnewswire.com/news-releases/akeso-announces-summit-therapeutics-and-ecog-acrin-cancer-research-group-enter-into-phase-iiiii-clinical-trial-collaboration-to-evaluate-ivonescimab-in-first-line-biliary-tract-cancer-302915469.html
https://www.roche.com/media/releases/med-cor-2026-10-21
https://clinicaltrials.gov/study/NCT04544449
https://www.tgtherapeutics.com/wp-content/uploads/2026/10/ENHANCE-600-mg_ECTRIMS-2026_Final-Poster_PDF.pdf
https://openai.com/index/openai-to-acquire-orchestra-bio/
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026
https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-first-pd-1-inhibitor-plus-antibody-drug-conjugate-regimen-for-adults-with-cisplatin-ineligibl/
https://www.roche.com/media/releases/med-cor-2026-09-30

FDA approved GSK's Hibsago (bepirovirsen) for selected adults with chronic hepatitis B without cirrhosis, opening a possible path off long-term treatment after a staged treatment and testing process. We examine who qualifies, the B-Well results and the boxed safety warnings. Amgen and AstraZeneca's detailed Phase 3 CROSSING results show Tezspire's biopsy remission and swallowing outcomes in eosinophilic esophagitis, where Dupixent is already established.

The daily roundup covers Rapport's RAP-219 bipolar mania results; TriGemX's proposed SPAC combination to fund migraine development; Veradermics' second Phase 3 hair-loss study; UroGen's UGN-103 filing acceptance; Nouscom's financing for cancer interception; Ambrose's AM-Pharma acquisition; and ICER's new-drug launch-price and prescription-access findings.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

FDA granted accelerated approval to GSK's Jemperli (dostarlimab) for biomarker-defined locally advanced rectal cancer, with continued surveillance required for responders. Disc Medicine's bitopertin met both Phase 3 APOLLO co-primary endpoints in erythropoietic protoporphyria after an earlier FDA rejection. The roundup covers Roche and Hansoh's oncology ADC deal, Merck KGaA's acquisition agreement for Silence Therapeutics in polycythemia vera, Lilly's Omvoh (mirikizumab) and Gilead's emvistegrast in ulcerative colitis. Also: AbbVie's ABBV-466 Crohn's data and EyePoint's DURAVYU Phase 3 miss in wet AMD and restructuring.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

The Pharma Closeout's AAO 2026 Debrief covers the readouts from the American Academy of Ophthalmology meeting in New Orleans that matter for drug, device and payer strategy. Kodiak's DAYBREAK and Ocular Therapeutix's SOL-1 show retina's durability race: fewer injections than fixed-schedule aflibercept, with Eylea HD and Vabysmo untested and the old standard going biosimilar. Belite Bio's tinlarebant heads to a February FDA decision in Stargardt disease, Beacon's VISTA data back a gene therapy filing, and Nanoscope's optogenetic therapy holds at four years. Plus geographic atrophy's next bets, two GLP-1 eye studies pointing in opposite directions, Lytenava's billing-code gap, and what to watch: the October 30 myopia advisory committee and the February 12 Stargardt decision.

0:00 Cold open and introduction

1:06 Story of the Congress: retina's durability race (Kodiak, Ocular, EyePoint)

4:29 The old standard goes biosimilar

5:08 Inherited retinal disease moves into the FDA queue: Belite, Beacon, Nanoscope

8:00 Geographic atrophy: PRIMA, K8 and OCU410

9:45 GLP-1 drugs and the eye: two studies, two directions

11:01 Roundup: Lytenava's billing code, Oculis, SpyGlass

12:14 What to watch: the myopia advisory committee and the Stargardt decision

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Fractyl Health reports that its investigational Revita met the six-month co-primary endpoint of the double-blind, sham-controlled REMAIN-1 pivotal study in adults who lost weight on tirzepatide and then stopped it; the twelve-month co-primary is expected in early 2027. Liquidia and United Therapeutics settled all pending patent litigation: Yutrepia stays available for PAH, Liquidia has asked FDA to remove PH-ILD from the label, and total obligations come to $380.7 million. Alex Mercer and Maya Patel cover Revita's safety and missing-data context, then turn to Verdiva's terminated switch-maintenance study, Biomea's BMF-650 Phase 1 data with its confined-placebo caveat, CHMP opinions for Lilly's oral Foundayo and for broadening Tryngolza in severe hypertriglyceridemia, Roche's ALK7 RNAi license from Rona, Zealand's AI-designed protein deal with Generate, and OMass Therapeutics' Series C. Also covered: Alaunos' completed Velaris acquisition and separate private placement; BMS's split admilparant Phase 3 and Syndax's IPF exit; Verastem's KRAS G12D pancreatic cohort and planned first-line Phase 3; CHMP opinions for Rasonque and Talvey; BNT113, Anktiva's papillary-only expansion and Nurix; tab-cel's accepted FDA resubmission; CHMP's confirmed negative opinion on re-examination for Omeros's narsoplimab; KB113 and RYZ101; Modus's sevuparin enrollment pause, Estuary's launch and Novartis's terminated iptacopan lupus nephritis study; maralixibat, obexelimab and garetosmab data; the Zilbrysq autoinjector, ARO-MAPT and Vanda's VQW-765 result and program hold; Anaphylm's FDA review date; FDA approvals for Enspryng in thyroid eye disease and RYZUMVI in presbyopia; interim six-year MIUDELLA data; Galderma's agreement to buy ZO Skin Health; Osivax's flu vaccine result; Pfizer's Enodia deal; IPOs from Iambic and City Therapeutics; China's export-control registration and draft catalog; a CMS proposed rule with PBM provisions; FDA's rare-disease framework initiative; and Marengo's upcoming ESMO presentation. The episode closes on the week's shared CHMP meeting and its different outcomes, the still-open question of weight maintenance after obesity drugs stop, and financings at different stages of completion.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Friday, October 16 edition.

Roche’s Enspryng wins FDA approval for thyroid eye disease as a home injection, while Omeros faces another negative European opinion for narsoplimab and plans to end compassionate use there. Alex Mercer and Maya Patel unpack the patient, evidence and commercial implications.

Also covered: Talvey’s proposed earlier-line use in Europe; Arrowhead’s early ARO-MAPT tau data in healthy volunteers; Foundayo’s European committee recommendations; RYZUMVI’s presbyopia approval; China’s draft drug-technology export controls; and Labcorp’s agreement to acquire select BioReference assets.

Recorded for Friday, October 16; released October 17 after a freshness check.

FDA expanded ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) to papillary-only bladder cancer by extrapolating earlier evidence. Vanda paused VQW-765 after its Phase 3 social-anxiety trial missed, while Vir and Gilead agreed a solid-tumor T-cell engager collaboration. The roundup covers a European recommendation for Revolution Medicines' daraxonrasib in pancreatic cancer, Osivax's OVX836 influenza-vaccine miss, and Alvotech/Advanz's AVT29 high-dose Eylea (aflibercept) biosimilar filing. Galderma's planned ZO Skin Health acquisition and OrbiMed's $3 billion in fund commitments round out the day.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

October 14, 2026 edition, released October 15, 2026. BioNTech's BNT113 missed progression-free survival in its pivotal head and neck cancer trial, leaving overall survival as the remaining path to a positive result. Roche licensed Rona Therapeutics' undisclosed ALK7-targeting RNAi obesity candidate—a fat-cell approach with most potential deal value contingent on milestones. Johnson & Johnson raised full-year guidance as newer medicines offset Stelara erosion; the roundup also covers FDA review of FYB206, a proposed Keytruda (pembrolizumab) biosimilar, Syndax ending axatilimab in IPF, 84-week Pasatru (garetosmab) data in FOP, and Tremfya (guselkumab) analyses in Crohn's perianal fistulas.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Monday, October 12, 2026 edition, released Tuesday, October 13, 2026. News checked through October 13, 2026; no material updates to the stories below were found.

Bristol's admilparant met its Phase 3 lung-function endpoint at the lower dose, while the higher dose missed significance in idiopathic pulmonary fibrosis. Its acquired RYZ101 program also delivered a Phase 3 win in neuroendocrine tumors after lutetium therapy, with benefit size still undisclosed. Mirum's LIVMARLI (maralixibat) reduced childhood itch in EXPAND, while the roundup covers First Tracks' ANB033 in celiac disease, Sebela's tegoprazan in reflux, Zenas' obexelimab in IgG4-related disease, Claris' eye-drop data and Ascelia's Orviglance regulatory path.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.